De+Klerk J.M., Van+het+Schip A.D., Zonnenberg B.A.
Phase 1 study of rhenium 186
HEDP in patients with bone metastases originating from breast cancer // J. Nucl. Med.
1996. V. 37(2). P. 249 252.
Delclos L., Jonhson G.C.
Palliative irradiation in breast cancer // Radiology. 1964.
V 83. P. 272 276.
De Lena M., Brambilla C., Morabito A, Bonadonna G.
Adriamycin plus vincristine
compared to and combined with cyclophsphamide, metotrexate and 5 fluoracil for
asvanced breast cancer // Cancer. 1975. V. 35. P.1108 1115.
De Lena M., Bonadonna G.
High dose medroxyprogesterone acetate of breast can
cer resistant to endocrine and cytotoxic therapy // Cancer Chem. and Pharm. 1979.
V. 2. P. 175 180.
De Lena M., Brandi M., Logroscino A, Lorusso V., Paradiso A., Maielo E.
Intravenous
administration of cyclophosphamide, metotrexate and 5 fluorouracil in metastatic breast.
A pilot study // Tumori. 1988. V. 74. P. 57 63.
De Luca L., Marcilio P., Rosa B.A.
La scintigrafia ossea in pazienti mastectomizzate,
sottoposte o no a chemioterapia // Minerva Med. 1983. V. 74. น 441. P. 2459
2464.
Della Cuna G.F., Calciati A., Strafo M., Bumma C., ัampio L.
High dose medrox
yprogestsrone acetate treatment: in metastatic carcinoma of the breast: a doseresponse eva
lution // Tumori. 1978. V. 64. P. 143 149.
Denardo S.J., Richman C.M., Goldstein D.S., Shen S., Salako Q., Kukis D.L., Meares
C.F., Yuan A., Welborn J.L., Denardo G.L.
Yttrium 90/indium 111 DOTA peptide
chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable
breast cancer // Anticancer Res. 1997. V. 17(3B). P. 1735 1744.
Deng H., Luo S., Tan T.
153 Sm EDTMP for moderate and severe bone cancer pain
// Hua. Hsi. I. Ko. Hsueh. Pao. 1995. V. 26(4). P. 391 394.
Dequecker J., Mbuyi+Muamba J.M., Holvort G.
Hydroxyproline and bone metastasis
// In: Bone metastasis: monitoring and treatment. Eds. Stoll B.A., Parbhoo S. New
York: Raven Press. 1983. P.181 199.
Derogatis L.R., Morrow G.R., Fetting J.
The prevalence of psychiatric disorders
among cancer patients // J.A.M.A. 1983. V. 249. P. 751 757.
Di Costanzo F., Gori S., Tonato M., Buzzi F., Clino L., Grignani F., Davis S.
Vindesine
and mitomycin C in chemotherapy refractory advanced breast cancer // Cancer. 1986.
V. 57. P. 904 907.
Diel I.J., Kaufmann M., Costa S.D., Holle R., von Minckwitz G., Solomayer E.F., Kaul
S., Bastert G.
Micrometastatic breast cancer cells in bone marrow at primary surgery: prog
nostic value in comparison with nodal status [see comments] // J. Natl. Cancer. Inst.
1996. V. 88(22). P. 1652 1658.
Diel I.J., Solomayer E.F.
Bisphosphonates in the antiosteolytic therapy of metastat
ic breast cancer // Zentralbl. Gynakol. 1996. V. 118. P. 1 5.
Diel I.J.
Bisphosphonates in the adjuvant therapy of breast cancer pathophysiolo
gy, animal models, and clinical experiences // Gynakol. Geburtshilfliche. Rundsch.
1998. V. 38(2). P. 64 71.
Diel I.J., Solomayer E.F., Costa S.D., Gollan C., Goerner R., Wallwiener D.,
Kaufmann M., Bastert G.
Reduction in new metastases in breast cancer with adjuvant clo
dronate treatment [see comments] // N. Engl. J. Med. 1998. V. 339(6). P. 357 363.
Dodwell D.J., Howell A.
The systemic treatment of bone metastases // In: Bone
metastases. Eds. Rubens R.D., Fogelman J. London: Springer. 1991. P. 121 129.
223
ส๎๑๒ํ๛ๅ ์ๅ๒เ๑๒เ็๛ ๐เ๊เ ์๎๋๎๗ํ๎้ ๆๅ๋ๅ็๛
